» Articles » PMID: 22751922

Evaluation of MAGE-A Expression and Grade of Dysplasia for Predicting Malignant Progression of Oral Leukoplakia

Overview
Journal Int J Oncol
Specialty Oncology
Date 2012 Jul 4
PMID 22751922
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

The risk of the malignant transformation of oral leukoplakia (OLP) is difficult to predict by histopathology. Melanoma-associated antigen-A (MAGE-A) expression is restricted to malignant cells and may be useful for the more accurate estimation of the potential malignant transformation of pre-malignant lesions. The aim of the present study was to investigate whether the expression of MAGE-A can be used to predict the malignant transformation of OLP. Paraffin-embedded tissue samples of OLP from 74 patients followed-up for at least 5 years were included. A total of 24 progressing and 50 non-progressing OLP, 18 corresponding tumor and 30 healthy mucosa specimens were analysed for MAGE-A 1, 3, 4, 6 10 and 12 expression by nested real‑time RT-PCR and graded for dysplasia. In total, 46% of the progressing lesions expressed at least 1 out of the examined MAGE-A antigens, whereas no expression was detected in any of the non-progressing OLP and normal specimens. The correlation between malignant transformation and MAGE-A expression was statistically significant (p=0.00001). Furthermore, 42% of the progressing OLPs without dysplasia (D0) expressed at least 1 antigen. The correlation between the grade of dysplasia and MAGE-A staining in the malignant transformation group was not significant (p=0.08). The detection of at least 1 MAGE-A antigen may allow the identification of high-risk lesions that may progress into carcinoma with time. Therefore, the investigation of MAGE-A expression should be assessed in order to obtain a more accurate evaluation of the potential cancer risk of OLP.

Citing Articles

The Follow-Up Necessity in Human Papilloma Virus-Positive vs. Human Papilloma Virus-Negative Oral Mucosal Lesions: A Retrospective Study.

Rushiti A, Castellani C, Cerrato A, Fedrigo M, Sbricoli L, Bressan E J Clin Med. 2024; 13(1).

PMID: 38202065 PMC: 10779469. DOI: 10.3390/jcm13010058.


Biomarkers of malignant transformation in oral leukoplakia: from bench to bedside.

Cai X, Zhang J, Zhang H, Li T J Zhejiang Univ Sci B. 2023; 24(10):868-882.

PMID: 37752089 PMC: 10522567. DOI: 10.1631/jzus.B2200589.


The Immune Cells in the Development of Oral Squamous Cell Carcinoma.

Caponio V, Zhurakivska K, Lo Muzio L, Troiano G, Cirillo N Cancers (Basel). 2023; 15(15).

PMID: 37568595 PMC: 10417065. DOI: 10.3390/cancers15153779.


Genetic Changes Driving Immunosuppressive Microenvironments in Oral Premalignancy.

Rangel R, Pickering C, Sikora A, Spiotto M Front Immunol. 2022; 13:840923.

PMID: 35154165 PMC: 8829003. DOI: 10.3389/fimmu.2022.840923.


Difficulties in the Prognostic Study of Oral Leukoplakia: Standardisation Proposal of Follow-Up Parameters.

Saldivia-Siracusa C, Gonzalez-Arriagada W Front Oral Health. 2022; 2:614045.

PMID: 35047990 PMC: 8757698. DOI: 10.3389/froh.2021.614045.